Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: Insights from the SENIORS trial

European Journal of Heart Failure

Volumn 11, Issue 9, 2009, Pages 872-880

  Cohen Solal, Alain ^a   Kotecha, Dipak ^b,c   Van Veldhuisen, Dirk J ^d   Babalis, Daphne ^b   Böhm, Michael ^e   Coats, Andrew J ^f   Roughton, Michael ^b   Poole Wilson, Philip ^c   Tavazzi, Luigi ^g   Flather, Marcus ^b,c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e SAARLAND UNIVERSITY   (Germany)

^f University of Sydney   (Australia)

^g GVM Hospitals of Care and Research   (Italy)

Author keywords

Beta blocker; Heart failure; Nebivolol; Renal impairment

Indexed keywords

NEBIVOLOL; PLACEBO; BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; ETHANOLAMINE DERIVATIVE; VASODILATOR AGENT;

AGED; ARTICLE; BRADYCARDIA; CAUSE OF DEATH; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE FUNCTION; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME; AGE; ANALYSIS OF VARIANCE; BLOOD; CONFIDENCE INTERVAL; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART STROKE VOLUME; KIDNEY; KIDNEY DISEASE; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; URINE; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BENZOPYRANS; CONFIDENCE INTERVALS; CREATININE; ETHANOLAMINES; FEMALE; GLOMERULAR FILTRATION RATE; HEART RATE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MULTIVARIATE ANALYSIS; STROKE VOLUME; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 69249154151     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp104     Document Type: Article

References (36)

1. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-962.
2. Huynh BC, Rovner A, Rich MW. Long-term survival in elderly patients hospitalized for heart failure: 14-year follow-up from a prospective randomized trial. Arch Intern Med 2006;166:1892-1898.
3. Velavan P, Khan NK, Goode K, Rigby AS, Loh PH, Komajda M, Follath F, Swedberg K, Madeira H, Cleland JG. Predictors of short term mortality in heart failure - Insights from the Euro Heart Failure survey. Int J Cardiol 2008, doi:10.1016/j.ijcard.2008.08.004. [Epub ahead of print].
4. Rich MW. Office management of heart failure in the elderly. Am J Med 2005;118: 342-348.
5. Saltzman HE, Sharma K, Mather PJ, Rubin S, Adams S, Whellan DJ. Renal dysfunction in heart failure patients: what is the evidence? Heart Fail Rev 2007;12:37-47.
6. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
7. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult- summary article. Circulation 2005;112:1825-1852.
8. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.
9. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJS, Poole-Wilson PA, Flather MD, Investigators S. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure). J Am Coll Cardiol 2009;53:2150-2158.
10. NationalKidney Foundation. Kidney disease outcomes quality initiative-clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. 2009; http://www.kidney.org/professionals/ kdoqi/guidelines-ckd/p4-class-g1.htm (6 January 2009).
11. Komajda M, Hanon O, Hochadel M, Lopez-Sendon JL, Follath F, Ponikowski P, Harjola V-P, Drexler H, Dickstein K, Tavazzi L, Nieminen M. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009;30:478-486.
12. Lenzen MJ, Boersma E, Reimer WJ, Balk AH, Komajda M, Swedberg K, Follath F, Jimenez-Navarro M, Simoons ML, Cleland JG. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 2005;26:2706-2713.
13. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898.
14. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-1936.
15. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-678.
16. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689.
17. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1587-1592.
18. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. b-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004;164:2465-2471.
19. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A. Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001;37:407-411.
20. DiBona GF, Sawin LL. Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. Circulation 1999;100:82-86.
21. Shlipak MG, Browner WS, Noguchi H, Massie B, Frances CD, McClellan M. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001;110:425-433.
22. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469-479.
23. Ghali JK, Wikstrand J, Van Veldhuisen DJ, Fagerberg B, Goldstein S, Hjalmarson A, Johansson P, Kjekshus J, Ohlsson L, Samuelsson O, Waagstein F, Wedel H, Group M-HS. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail 2009;15: 310-318.
24. Georgescu A, Pluteanu F, Flonta M-L, Badila E, Dorobantu M, Popov D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005;508:159-166.
25. Ignarro LJ, Byrns RE, Trinh K, Sisodia M, Buga GM. Nebivolol: a selective [beta]1-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 2002;7:75-82.
26. Sule SS, Frishman W. Nebivolol: New therapy update. Cardiol Rev 2006;14: 259-264.
27. Khan W, Deepak SM, Coppinger T, Waywell C, Borg A, Harper L, Williams SG, Brooks NH. fbetag blocker treatment is associated with improvement in renal function and anaemia in patients with heart failure. Heart 2006;92:1856-1857.
28. van de Borne P, Fici F, Makel W, Fiasse A, Degaute J, Leeman M. The effect of nebivolol and atenolol on renal and systemic haemodynamics in hypertensive patients. High Blood Pres Cardiovasc Prev 2007;14:133-137.
29. Damman K, Navis G, Smilde TDJ, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007;9:872-878.
30. ClinicalTrials.gov-Beta-blockers in Heart Failure Collaborative Group. Collaborative systematic overview of randomised controlled trials of beta-blockers in the treatment of heart failure (BB-META-HF). http://clinicaltrials.gov/ct2/ show/NCT00832442 (3 February 2009).
31. Dobre D, van Veldhuisen DJ, Mordenti G, Vintila M, Haaijer-Ruskamp FM, Coats AJS, Poole-Wilson PA, Flather MD. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007;154:109-115.
32. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-827.
33. Nangaku M, Eckardt K-U. Pathogenesis of renal anemia. Semin Nephrol 2006;26: 261-268.
34. O'Meara E, Chong KS, Gardner RS, Jardine AG, Neilly JB, McDonagh TA. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Fail 2006;8:63-67.
35. Smilde TDJ, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-1580.
36. Chiara M, Eric DP, Anita YC, Lynda AS, Newby LK, Robert AH, Gibler WB, Ohman EM, Sarah AS, Matthew TR, Karen PA. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2008;51:991-996.